Factors Governing the Accuracy of Subvisible Particle Counting Methods.
暂无分享,去创建一个
Hanns-Christian Mahler | Christof Finkler | Joerg Huwyler | Roland Schmidt | Anacelia Ríos Quiroz | Atanas V Koulov | A. Koulov | J. Huwyler | Atanas V. Koulov | Anacelia Ríos Quiroz | R. Schmidt | Christof Finkler | Hanns-Christian Mahler
[1] S. Singh,et al. An industry perspective on the monitoring of subvisible particles as a quality attribute for protein therapeutics. , 2010, Journal of pharmaceutical sciences.
[2] Wei Wang,et al. Immunogenicity of protein aggregates--concerns and realities. , 2012, International journal of pharmaceutics.
[3] W. Jiskoot,et al. Light Obscuration Measurements of Highly Viscous Solutions: Sample Pressurization Overcomes Underestimation of Subvisible Particle Counts , 2014, The AAPS Journal.
[4] J. Carpenter,et al. Characterization of Nanoparticle Tracking Analysis for Quantification and Sizing of Submicron Particles of Therapeutic Proteins. , 2015, Journal of pharmaceutical sciences.
[5] John F. Carpenter,et al. Analytical approaches to assess the degradation of therapeutic proteins , 2013 .
[6] G. Winter,et al. How subvisible particles become invisible-relevance of the refractive index for protein particle analysis. , 2013, Journal of pharmaceutical sciences.
[7] Steven Kozlowski,et al. Overlooking subvisible particles in therapeutic protein products: gaps that may compromise product quality. , 2009, Journal of pharmaceutical sciences.
[8] D. K. Sharma,et al. Micro-Flow Imaging: Flow Microscopy Applied to Sub-visible Particulate Analysis in Protein Formulations , 2010, The AAPS Journal.
[9] Patrick Garidel,et al. Strategies for the Assessment of Protein Aggregates in Pharmaceutical Biotech Product Development , 2010, Pharmaceutical Research.
[10] A. Koulov,et al. Factors Governing the Precision of Subvisible Particle Measurement Methods – A Case Study with a Low-Concentration Therapeutic Protein Product in a Prefilled Syringe , 2015, Pharmaceutical Research.
[11] M. Manning,et al. Flow imaging: moving toward best practices for subvisible particle quantitation in protein products. , 2013, Journal of pharmaceutical sciences.
[12] John F Carpenter,et al. Critical evaluation and guidance for using the Coulter method for counting subvisible particles in protein solutions. , 2012, Journal of pharmaceutical sciences.
[13] M. Peterka,et al. Evaluation of nanoparticle tracking analysis for total virus particle determination , 2012, Virology Journal.
[14] W. Jiskoot,et al. Micro-flow imaging and resonant mass measurement (Archimedes)--complementary methods to quantitatively differentiate protein particles and silicone oil droplets. , 2013, Journal of pharmaceutical sciences.
[15] Doris W Lau,et al. Quantification and characterization of micrometer and submicrometer subvisible particles in protein therapeutics by use of a suspended microchannel resonator. , 2012, Analytical chemistry.
[16] S. Manalis,et al. Weighing of biomolecules, single cells and single nanoparticles in fluid , 2007, Nature.
[17] S. Manalis,et al. Integrated measurement of the mass and surface charge of discrete microparticles using a suspended microchannel resonator. , 2009, Analytical chemistry.
[18] L. Narhi,et al. A critical review of analytical methods for subvisible and visible particles. , 2009, Current pharmaceutical biotechnology.
[19] G. Vayopoulos,et al. Antiretroviral activity of 5-azacytidine during treatment of a HTLV-1 positive myelodysplastic syndrome with autoimmune manifestations , 2012, Virology Journal.
[20] Matthew N. Rhyner. The Coulter Principle for Analysis of Subvisible Particles in Protein Formulations , 2011, The AAPS Journal.
[21] M. Sukumar,et al. Quantification and characterization of subvisible proteinaceous particles in opalescent mAb formulations using micro-flow imaging. , 2010, Journal of pharmaceutical sciences.
[22] J. Carpenter,et al. Characterization and quantitation of aggregates and particles in interferon-β products: potential links between product quality attributes and immunogenicity. , 2013, Journal of pharmaceutical sciences.
[23] Daniela Verthelyi,et al. Managing uncertainty: a perspective on risk pertaining to product quality attributes as they bear on immunogenicity of therapeutic proteins. , 2012, Journal of pharmaceutical sciences.
[24] M. Wright. Nanoparticle tracking analysis for the multiparameter characterization and counting of nanoparticle suspensions. , 2012, Methods in molecular biology.
[25] G. Winter,et al. Pharmaceutical feasibility of sub-visible particle analysis in parenterals with reduced volume light obscuration methods. , 2013, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[26] A. Koulov,et al. Measuring Subvisible Particles in Protein Formulations Using a Modified Light Obscuration Sensor with Improved Detection Capabilities. , 2015, Analytical chemistry.
[27] D. Volkin,et al. Effect of solution properties on the counting and sizing of subvisible particle standards as measured by light obscuration and digital imaging methods. , 2014, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[28] J. Philo. Is any measurement method optimal for all aggregate sizes and types? , 2006, The AAPS Journal.
[29] A. Koulov,et al. Discrimination Between Silicone Oil Droplets and Protein Aggregates in Biopharmaceuticals: A Novel Multiparametric Image Filter for Sub-visible Particles in Microflow Imaging Analysis , 2011, Pharmaceutical Research.
[30] Wim Jiskoot,et al. Particles in therapeutic protein formulations, Part 1: overview of analytical methods. , 2012, Journal of pharmaceutical sciences.
[31] D. Volkin,et al. Calculating the mass of subvisible protein particles with improved accuracy using microflow imaging data. , 2015, Journal of pharmaceutical sciences.
[32] T. Arvinte,et al. Addressing new analytical challenges in protein formulation development. , 2011, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[33] W. Jiskoot,et al. Flow Imaging Microscopy for Protein Particle Analysis—A Comparative Evaluation of Four Different Analytical Instruments , 2013, The AAPS Journal.
[34] S. Shire,et al. Characterization of Particles in Protein Solutions: Reaching the Limits of Current Technologies , 2010, The AAPS Journal.
[35] Elizabeth M. Topp,et al. Analyzing Subvisible Particles in Protein Drug Products: a Comparison of Dynamic Light Scattering (DLS) and Resonant Mass Measurement (RMM) , 2014, The AAPS Journal.
[36] S. Mathew,et al. Characterization of submicron (0.1-1 μm) particles in therapeutic proteins by nanoparticle tracking analysis. , 2015, Journal of pharmaceutical sciences.
[37] Vasco Filipe,et al. Critical Evaluation of Nanoparticle Tracking Analysis (NTA) by NanoSight for the Measurement of Nanoparticles and Protein Aggregates , 2010, Pharmaceutical Research.
[38] A. Mire-Sluis,et al. Sub-visible particle quantitation in protein therapeutics. , 2009, Pharmeuropa bio & scientific notes.